Entrepreneurship & Innovation · Innovation Management

From Lab to Market — Commercialize AeroFoam-7 at NorTec Transfer Office

A four-round, advanced technology-transfer simulation set inside NorTec Transfer Office, the knowledge-transfer unit of a Porto-based research university operating from the U.Porto innovation ecosystem (EUR 1.8M annual budget, six-person team, 23 disclosed inventions).

4 rounds Executive English, Español

Preview

About this simulation

A four-round, advanced technology-transfer simulation set inside NorTec Transfer Office, the knowledge-transfer unit of a Porto-based research university operating from the U.Porto innovation ecosystem (EUR 1.8M annual budget, six-person team, 23 disclosed inventions).

Two clocks collide on 16 June 2026: AeroFoam-7 — a recyclable aerogel insulation material with strong lab data but stuck at Technology Readiness Level 4 — must enter the PCT patent national phase within 90 days (≈EUR 180,000) or lose protection in key markets, and the same quarter the discretionary EUR 600,000 proof-of-concept seed fund's reporting period closes, clawing back anything unspent.

Industrial buyers want TRL 7, and closing the valley of death needs ≈EUR 450,000 plus 9–12 months of field validation — so internal money alone cannot both protect and de-risk the asset and external leverage is mandatory.

Playing the Tech-Transfer Manager you (1) diagnose readiness and value honestly, naming the binding constraint as the TRL-4-to-7 readiness gap rather than treating lab data as sale-ready; (2) choose the commercialization model — exclusive license, inventor spin-off, or a co-funded joint-development agreement — matching pathway to the technology's maturity, the lead inventor's reluctance to leave academia, and the capital available; (3) allocate the EUR 600k seed fund across national-phase filing, field validation and a reserve, decide which jurisdictions to file in versus abandon, and pick a partner among a multinational's EUR 250k + 3% royalty exclusive license, a regional construction group's EUR 400k co-funded JDA with a future option, or a venture fund's EUR 1.2M for 35% equity conditional on the inventor leaving; and (4) sequence the next 12 months around the hard deadlines, set exit KPIs, and build a contingency for inventor exit or weak validation.

The math rewards genuine funding leverage (≥1.5× external euros per internal euro), context-fit pathway choice and deadline-driven sequencing, and punishes the five classic errors — upside-chasing into a founderless spin-off, leverage blindness, control surrender to a conflicted incumbent, IP over-filing, and readiness denial.

Final KPIs track Readiness (TRL progress), Funding Leverage, Value Capture and seed-fund Budget used against the EUR 600k cap.

Who it is for

An advanced simulation for participants used to working with the main frameworks and trade-offs of the subject, designed for executive education and experienced professionals.

How a session runs

  1. The instructor creates a session from the Eureka dashboard and invites the participants.
  2. Participants play 4 rounds. In each one they submit their decisions and the simulation calculates the results.
  3. The simulation can be run in English, Español.
  4. The instructor follows each participant's progress and results from the dashboard, and uses the class results for the debrief.

Decisions participants make

The decisions participants make during the simulation:

  • What is the binding constraint between AeroFoam-7 and the market?
  • What evidence does TRL 7 actually require — and do you admit you lack it?
  • How honestly does your team rate the readiness gap (vs. believing the lab hype)? (%)
  • Which commercialization model fits a TRL-4 asset with a reluctant inventor and two colliding clocks?
  • At what milestone does value (and risk) transfer to the partner?
  • How firmly do you match the pathway to context rather than chasing the headline upside? (%)
  • Allocate the €600k seed fund across these uses (in €k; reserve is whatever is left)
  • Which jurisdictions do you enter national phase in?
  • Which partner do you sign to close the funding gap?
  • How do you sequence the next 12 months against the hard Day-90 deadlines?

What participants track

What participants follow on screen as the rounds go by:

  • Readiness, Leverage & Value Trajectory

Subjects covered

Designed for courses in Innovation Management.

Ready to use From Lab to Market — Commercialize AeroFoam-7 at NorTec Transfer Office with your students?

Contact us and we'll set you up with a free trial session.

Contact us